At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 211 enrolled
Drug / intervention
AZD0530 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
In Brief
A Phase 2 clinical trial evaluating AZD0530, Carboplatin, and 1 other intervention for Ovarian Neoplasms and Ovarian Cancer. Completed, enrolled 211 participants across 50 sites in 12 countries.
Detailed Summary
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms, Ovarian Cancer
CountriesBulgaria, Canada, Denmark, France, Netherlands, Norway, Peru, Portugal, Romania, Russia, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartApr 2008
Primary CompletionAug 2009
Study CompletionJan 2012
TodayJul 2026
First PostedFeb 8, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2009
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.4 years ago
Interventions
AZD0530drug
oral once daily dose
Carboplatindrug
intravenous injection
Paclitaxeldrug
intravenous infusion